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$7,098 among those switching, discontinuing or persisting,
respectively. The costs associated with switching and discontinu-
ing treatment were signiﬁcantly higher (p < 0.0001) than with
persistence, even when adjusting for patient characteristics, MS
drug use, and medical costs during the six months preceding
treatment start. Hospitalizations were the primary source of the
increased costs (means of $2597, $2191, and $1160 for switch-
ing, discontinuing, and persisting, respectively). CONCLUSION:
One year after treatment initiation with index drug, over a third
of MS patients discontinue or switch ABCR treatment and incur
higher hospitalization related medical costs than those persisting
with therapy. Discontinuation or switches due to potential sub-
optimal treatment and subsequent hospitalizations may be driven
by disease relapses, suggesting a need for more highly effective
MS therapies.
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OBJECTIVE: To assess the cost-effectiveness of pregabalin in
the treatment of ﬁbromyalgia (FM) from a US perspective.
METHODS: We developed a micro-simulation model to assess
the cost-effectiveness of pregabalin therapy (450 mg/d) in a hypo-
thetical cohort of patients with moderate or worse pain due to
FM. The model simulates pain experience on a weekly basis over
14 weeks, using data from a randomized, placebo-controlled
clinical trial. Pain levels were estimated using an 11-point
numeric rating scale; moderate or worse pain was assumed to be
a pain score 4. Health-state utilities were assigned based on
estimated pain level, using published values for the Health Utili-
ties Index [HUI]—Mark II. Costs of drug therapy only were
considered. Cost-effectiveness of pregabalin therapy was consid-
ered alternatively versus placebo and no therapy, the latter
because pregabalin is the only drug currently indicated for the
treatment of FM. Cost-effectiveness was expressed in terms of
both incremental cost per additional day without moderate or
worse pain and incremental cost per quality-adjusted life-year
(QALY) gained. RESULTS: In comparison with no treatment,
pregabalin therapy was estimated to yield an average of 29.4
additional days without moderate or worse pain over 14 weeks,
and a gain of 0.019 QALYs. Corresponding estimates for the
comparison with placebo were 11.4 additional days without
moderate or worse pain, and 0.009 additional QALYs. Assuming
a daily cost of therapy of $3.30, the incremental cost (95% CI) of
pregabalin therapy per additional day without moderate or
worse pain was $11 ($9, $14) versus no treatment, and $32 ($18,
$72) versus placebo. Corresponding estimates of the incremental
cost per QALY gained were $39,266 ($27,167, $57,269)
and $17,220 ($15,289, $20,153), respectively. CONCLUSION:
In patients with moderate or worse pain due to FM, the
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OBJECTIVE: Studies in patients with multiple sclerosis (MS)
have shown that disease-modifying drugs (DMDs) lower the
frequency and severity of relapses and slow disease progression.
The clinical and economic consequences of regimens involving
switches between DMDs have not been studied fully. The fol-
lowing analysis sought to examine clinical and economic out-
comes in MS patients who switch from one of the two leading
DMDs in the United States (IFNb-1a intramuscular [IM] and
glatiramer acetate [GA]) to a high-dose high-frequency (HDHF)
interferon beta (IFNb-1b subcutaneous [SC], IFNb-1a SC) or
natalizumab, a second-line agent. METHODS: A previously
published pharmacoeconomic model was modiﬁed to evaluate
switching scenarios and estimate total cost of MS care and the
number of relapses avoided over a four year period. The model
assumes that switches from the ﬁrst agent occurred at the end of
the ﬁrst year and that the second agent is continued through the
end of the four year period. Clinical data inputs were derived
from Class I clinical trials. The costs of relapses and disability
steps were based on published literature, and drug prices were
obtained from the Red Book. Relative cost-effectiveness
between switching scenarios was compared by calculating the
cost per relapse avoided over the four year time frame.
RESULTS: The cost of avoiding one relapse in patients switch-
ing from IFNb-1a IM to IFNb-1a SC or IFNb-1b SC was
$84,401 and $87,090, respectively. The most costly switch was
from IFNb-1a IM to natalizumab ($104,568 per relapse
avoided). Switching from GA to IFNb-1a SC, IFNb-1b SC, or
natalizumab resulted in costs per relapse avoided of $70,822,
$73,511, and $90,989, respectively. CONCLUSION: This
analysis suggests that MS patients switched from IFNb-1a IM
or GA to an HDHF IFNb beneﬁted from the lowest cost to
avoid a relapse.
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OBJECTIVE: Triptans (almotriptan, eletriptan, naratriptan,
rizatriptan, sumatriptan, and zolmitriptan) have become the pre-
ferred migraine therapy in Canada and elsewhere. Currently,
health care decision makers are considering developing a consis-
tent listing policy for triptans in publicly-funded drug plans
across Canada. Compelling evidence on cost-effectiveness of trip-
tans applicable to Canadian health care setting is important in
aiding decision-making process. This study examines the validity
and applicability of available evidence of cost-effectiveness
studies of triptans to the Canadian health care system.
METHODS: Cost-effectiveness studies were obtained by search-
ing PubMed and the Cochrane Library and cross-searching
BIOSIS Previews®, EMBASE®, and MEDLINE® databases on
the OVID® search system. A Systematic review was performed
on selected studies. The validity of evidence was assessed by
appraising each study with regards to inclusion of all triptans;
major costs and beneﬁts in the model; resource use in the model;
and use of credible clinical data. RESULTS: Twelve relevant
studies were identiﬁed and reviewed. Of them, two considered
major cost and beneﬁts and resources use but compared only a
few triptans and used unreliable clinical data; eight studies con-
sidered only drug cost with only two out of eight studies com-
pared all triptans using unreliable clinical data; and two studies
considered resource use and major costs/beneﬁts, compared only
a few triptans, and used unreliable clinical data. CONCLUSION:
Available studies on cost-effectiveness of triptans are of limited
utility to Canadian decision markers as they harbour ﬂaws such
as failure to compare all triptans, adoption of less credible clini-
cal estimates, exclusion of major costs/beneﬁts, and failure to
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model resources use. A reliable clinical and primary cost-
effectiveness study is warranted to take into account Canadian
publicly-funded health care system.
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OBJECTIVE: Epilepsy represents a national health problem. In
Mexico there are between 1.2 and 2.2 million diagnosed patients
who raise the demand for health care services. The aim of this
study was to analyze which antiepileptic drug is a cost-effective
therapy as an adjuvant treatment for the management of refrac-
tory partial seizures using a health care payer’s perspective.
\METHODS: A three-stage Markov model was used with a
follow-up period of one-year (4 cycles). Effectiveness measures
were the percentage of patients under control (no seizures) and
the number of hospitalizations avoided. The transition probabili-
ties were obtained from national and international published
literature. Comparators used in the assessment were topira-
mate (300–800 mg/day), levetiracetam (2000–3000 mg/day),
gabapentin (1200–1800 mg/day), lamotrigine (75–400 mg/day),
vigabatrin (1000–3000 mg/day) and pregabalin (150–600 mg/
day). Estimation of resource use was performed employing
hospital records from hospitals of the Social Security Mexican
Institute (IMSS). They include days of hospitalization, emer-
gency, outpatient services and drugs costs. The model was cali-
brated and probabilistic sensitivity analyses were conducted
using bootstrapping techniques. RESULTS: The highest rate of
controlled-patients was for pregabalin (54.1%;CI95% 53.3%–
55.1%) followed by topiramate (42.2%;CI95%41.5%–43.1%);
levetiracetam (34.1%;CI95% 33.4%–34.8%); vigabatrin
(32.6%;CI95% 32.0%–33.4%); gabapentin (27.4%;CI95%
26.9%–28.1%) and lamotrigine (24.7%;CI95% 24.1%–
25.3%). The annual expected mean cost per patient resulted
in US$3136.4 (CI95% US$3076.2–US$3139.8) for pregabalin;
US$4295.9 (CI95% US$4269.8–US$4318.3) for topiramate;
US$4037.7 (CI95% US$4015.6–US$4059.8) for levetirace-
tam; US$3470.9 (CI95% US$3450.1–US$3493.3) for
vigabatrin; US$3581.6 (CI95% US$3,552.3–US$3615.8) for
gabapentin; and US$2807.2 (CI95% US$2789.1–US$2825.4)
for lamotrigine. The ICER’s of the alternatives choosing
gabapentin as the gold standard were -US$1,769 (CI95%,
-US$1,685.3–US$1,812.8) for pregabalin, US$4,826.5 (CI95%
US$4,143.7–US$4,895.8) for topiramate; US$6,807.9 (CI95%
US$5,821.4–US$6986.7) for levetiracetam; -US$2,127.9
(CI95% -US$2,381.8,-US$1,561.2) for vigabatrin and
US$28,681.6 (CI95% US$28,569.1–US$49,547.0) for lamot-
rigine. Acceptability curves and component analyses showed that
these results remain robust. CONCLUSION: Pregabalin demon-
strated to be a cost-saving and cost-effectiveness adjuvant
therapy in the management of refractory partial seizures in
Mexican patients.
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OBJECTIVE: Natalizumab is a new disease modifying therapy
currently licensed for use in patients with relapsing-remitting
multiple sclerosis (RRMS), and has recently been the subject of a
cost-effectiveness evaluation by the National Institute for Health
and Clinical Excellence (NICE) in the UK. NICE accepted that
natalizumab was cost-effective in a highly-active subgroup of
RRMS patients, but not in all patients failing on current therapy
(sub-optimal therapy, SOT patients). In the SOT patients, the
basecase ICERs exceeded £43,400 and NICE essentially con-
cluded that natalizumab would not be a cost-effective use of NHS
resources in these patients unless they were having two or more
relapses per year. However, NICE recognised that the evaluation
may have underestimated the incremental QALY in two areas.
The ﬁrst was that the relapse disutility was underestimated, and
the second was that the time horizon of the evaluation was too
short. Here we re-evaluated the ICERs for natalizumab vs.
interferon-beta and glatiramer acetate in SOT patients taking
into account the points raised by NICE. METHODS: The origi-
nal model submitted to NICE was a 20-year markov-model
parameterised for the UK from a direct health care perspective.
Disutilities for relapse were updated using values from a previous
UK Health Technology Assessment, and the cost of relapse was
changed in line with contemporary studies. The time-horizon for
the model was extended from 20 years to 30 years. RESULTS:
The ICER from a direct medical costs perspective for natali-
zumab vs. interferon-beta was £29,900 per QALY. For natali-
zumab vs. glatiramer acetate the ICER was £29,300 per QALY.
CONCLUSION: The European Medicines Evaluation Agency
has approved natalizumab for use in highly active RRMS, includ-
ing SOT patients. Given the willingness-to-pay threshold of
£30,000 per QALY commonly associated with NICE guidance,
the results here show that natalizumab is a cost-effective treat-
ment for all patients failing on current therapy in the UK.
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OBJECTIVE: To determine the incremental cost-utility ratio
(ICUR) of Sativex®, a novel, cannabis-based therapy, as ad-
junctive treatment for neuropathic pain in MS adults from a
Canadian provincial government payer perspective over a one-
year time horizon. METHODS: Efﬁcacy and safety of Sativex®
were extracted from the pivotal phase III trial comparing
Sativex®+standard analgesic care (SAC) to SAC alone. Direct
medical resources (medication, health professionals, lab and
diagnostic) were taken from a burden of illness study. Sativex®
utilization for the economic analysis was based on the utilization
in the pivotal study (# sprays per day). Costs (2006 CND$) were
based on provincial sources. Utilities were based on a mapping
exercise whereby pain severity (BS-11) from the pivotal trial was
mapped onto Health Utilities Index Mark 3 (HUI) pain attribute
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